In the global pharmaceutical industry's transformation towards "innovation, sustainability, and integration," CDMOs (Contract Development and Manufacturing Organizations) and CMOs (Contract Manufacturing Organizations), as core hubs of the pharmaceutical supply chain, play a vital role in connecting drug research and development with commercial production, thereby driving the industry's efficient development. NEEQ-listed Jingjing Pharmaceutical Co., Ltd. (NEEQ: 835033), a company specializing in domestically produced active pharmaceutical ingredients (APIs), embodies the core philosophy of CDMOs with its integrated "R&D + production + services" model. By leveraging three core technologies, the company has established a competitive edge in niche areas such as sterile APIs and pharmaceutical intermediates, paving a unique and robust development path. Its CDMO/CMO services are rooted in technological innovation, utilizing crystallization control, bioenzyme catalysis, and synthetic biology to break through the homogenization of the industry and provide customized solutions that go beyond customer expectations. The company's technical prowess not only enhances production capabilities but also builds trust with high-end clients. Jingjing Pharmaceutical has long been dedicated to the pharmaceutical ingredients sector, focusing on high-tech segments and creating a competitive advantage that is difficult to replicate. Its crystallization control technology allows for precise control of key physical properties such as particle size distribution, bulk density, and fluidity, perfectly meeting the needs of customers in the sterile powder injection market. This technology enables the company to meet the stringent requirements of injectable drug production, making it a preferred partner for high-end clients. Products produced using this technology, such as sterile arginine, avibactam sodium, and alanylglutamine, have gained significant market recognition. Bioenzyme catalysis technology aligns with global efforts towards carbon neutrality and sustainable production, offering high efficiency and reduced environmental impact while significantly lowering production costs and emissions. The company has utilized this technology to industrialize amino acid derivatives, continuously advancing technological innovation and product expansion in this field. In recent years, synthetic biology has become a focal point for pharmaceutical innovation. Jingjing Pharmaceutical has invested in this area, establishing a liposomal delivery platform based on synthetic biology to overcome limitations in the application of bioactive components. The company's innovative liposomal platform, expected to be launched in 2025, includes products like AKG (α-ketoglutaric acid) and AKG-Ca, which will expand its business beyond the pharmaceutical sector into food, agriculture, and cosmetics. Jingjing Pharmaceutical's CDMO/CMO services cover the entire value chain, addressing customers' needs at every stage of development and production. With its integrated "R&D + production + quality + registration" approach, the company can handle various production scales, from small-scale research to large-scale manufacturing. In the CMO segment, it offers personalized packaging options (e.g., 5kg/桶, 10kg/桶) to accommodate different stages of client requirements. Its dedicated sterile production lines and GMP-compliant systems ensure consistent product quality across large-scale production. The company's expertise in chemical and biological synthesis enables it to customize pharmaceutical intermediates, providing end-to-end services from laboratory trials to industrial production. Its comprehensive quality management system supports clients in API registration and shortens the time to market. As the pharmaceutical industry continues to evolve, Jingjing Pharmaceutical is poised to lead the way in CDMO/CMO services with its differentiated technology, strategic focus, and comprehensive services. It is committed to empowering the industry through technology and earning trust through exceptional services. In the new era of high-quality pharmaceutical development, Jingjing Pharmaceutical is poised to become a key player in the CDMO for specialty APIs, contributing to the innovative growth of the global pharmaceutical industry.